Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Entera Bio Ltd. (ENTX : NSDQ)

• Company Description    Entera Bio Ltd. is a clinical-stage biopharmaceutical company. It focused on the development and commercialization of orally delivered molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an oral formulation of parathyroid hormone for hypoparathyroidism and osteoporosis. Entera Bio Ltd. is based in Jerusalem, Israel. Number of Employees: 20

• Price / Volume Information    Yesterday's Closing Price: $1.80 Daily Weekly Monthly 20 Day Moving Average: 71,632 shares Shares Outstanding: 45.66 (millions) Market Capitalization: $82.19 (millions) Beta: 1.69 52 Week High: $2.79 52 Week Low: $1.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.63% -10.24% 12 Week -9.55% -17.84% Year To Date -15.09% -22.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL KIRYAT HADASSAH MINRAV BUILDING FIFTH FLOOR - JERUSALEM,L3 9112002 ISR ph: 972-2532-7151 fax: - investorrelations@enterabio.com http://www.enterabio.com

• General Corporate Information    Officers Miranda Toledano - Chief Executive Officer and Director Gerald Lieberman - Chairman of the Board of Directors Hillel Galitzer - Chief Operating Officer Dana Yaacov-Garbeli - Chief Financial Officer Sean Ellis - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M40527109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/14/25 Share - Related Items Shares Outstanding: 45.66 Most Recent Split Date: (:1) Beta: 1.69 Market Capitalization: $82.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.74 Price/Cash Flow: - Price / Sales: 368.58 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -48.78% ROE 06/30/25 - -77.75 03/31/25 - -95.10 12/31/24 - -119.54 ROA 06/30/25 - -68.13 03/31/25 - -82.77 12/31/24 - -102.03 Current Ratio 06/30/25 - 10.47 03/31/25 - 13.07 12/31/24 - 7.63 Quick Ratio 06/30/25 - 10.47 03/31/25 - 13.07 12/31/24 - 7.63 Operating Margin 06/30/25 - - 03/31/25 - -4,525.11 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - -4,525.11 12/31/24 - - Pre-Tax Margin 06/30/25 - -6,378.31 03/31/25 - -4,518.83 12/31/24 - -5,263.54 Book Value 06/30/25 - 0.38 03/31/25 - 0.43 12/31/24 - 0.23 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©